[Hepatitis B: who should be treated?]

Area of Science:

• Hepatology
• Virology
• Internal Medicine

Background:

• Current hepatitis B virus (HBV) therapies demonstrate limited efficacy in eradicating infection, with minimal treatment success advancements in recent years.
• Existing Croatian consensus guidelines from 2005 and 2009 require updates based on international recommendations from AASLD (2009), EASL (2012), and APASL (2012).

Purpose of the Study:

• To review recent advancements in hepatitis B management, focusing on updates to Croatian consensus guidelines.
• To highlight new developments in noninvasive fibrosis assessment, HBsAg quantification for treatment outcome prediction, and newly registered drugs.
• To provide recommendations for rational and efficient treatment strategies, including special patient populations.

Main Methods:

• Comparative analysis of Croatian guidelines (2005, 2009) with international consensus statements (AASLD 2009, EASL 2012, APASL 2012).
• Review of new developments in diagnostic tools, including noninvasive fibrosis assessment and HBsAg quantification.
• Inclusion of new drug registrations and updated treatment recommendations.

Main Results:

• Significant updates are proposed for hepatitis B treatment protocols, incorporating international standards.
• Noninvasive methods for liver fibrosis assessment and HBsAg quantification are emphasized for predicting treatment response.
• New recommendations address the management of specific patient groups, including pregnant women, those with drug resistance, co-infections, and post-transplant patients.

Conclusions:

• The updated guidelines aim to improve the efficiency and rationality of hepatitis B treatment.
• Incorporating novel diagnostic and therapeutic advancements is crucial for enhancing treatment outcomes.
• Specialized recommendations are provided for managing complex cases of hepatitis B infection.